10x Genomics/$TXG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Ticker
$TXG
Sector
Primary listing
Employees
1,306
Headquarters
Website
10x Genomics Metrics
BasicAdvanced
$1.7B
-
-$0.69
2.03
-
Price and volume
Market cap
$1.7B
Beta
2.03
52-week high
$17.25
52-week low
$6.78
Average daily volume
2.7M
Financial strength
Current ratio
5.843
Quick ratio
5.047
Long term debt to equity
9.967
Total debt to equity
11.218
Interest coverage (TTM)
-28,881.00%
Profitability
EBITDA (TTM)
-114.568
Gross margin (TTM)
69.56%
Net profit margin (TTM)
-13.13%
Operating margin (TTM)
-23.02%
Effective tax rate (TTM)
-6.65%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-9.45%
Return on equity (TTM)
-11.30%
Valuation
Price to revenue (TTM)
2.613
Price to book
2.2
Price to tangible book (TTM)
2.26
Price to free cash flow (TTM)
29.613
Free cash flow yield (TTM)
3.38%
Free cash flow per share (TTM)
0.465
Growth
Revenue change (TTM)
2.02%
Earnings per share change (TTM)
-65.74%
3-year revenue growth (CAGR)
8.98%
3-year earnings per share growth (CAGR)
-18.30%
What the Analysts think about 10x Genomics
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
Bulls say / Bears say
Acquisition of Scale Biosciences for $30 million strengthens the Chromium platform and expands single-cell analysis capabilities, positioning 10x Genomics to address broader market needs (Investing.com).
Initial shipments of Visium HD 3' and HD cell segmentation enhance high-resolution profiling, potentially driving increased consumables usage and customer adoption (BioSpace).
Robust liquidity with $447.3 million in cash and marketable securities at the end of Q2 provides financial flexibility for R&D and strategic investments (PR Newswire).
Instrument revenue declined 39% year-over-year in Q2 2025 as capital-expenditure constraints weighed on sales, signaling weakened demand for 10x Genomics’ high-margin products (Investing.com).
The company withdrew full-year 2025 guidance and cut 8% of its workforce amid persistent uncertainty in academic and government research funding, undermining visibility and operational stability (GenomeWeb).
High-cost instrument sales have faced sharp declines due to NIH funding cuts and policy shifts, causing purchasing hesitancy that negatively impacts top-line growth (Barron's).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
10x Genomics Financial Performance
Revenues and expenses
10x Genomics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 10x Genomics stock?
10x Genomics (TXG) has a market cap of $1.7B as of October 25, 2025.
What is the P/E ratio for 10x Genomics stock?
The price to earnings (P/E) ratio for 10x Genomics (TXG) stock is 0 as of October 25, 2025.
Does 10x Genomics stock pay dividends?
No, 10x Genomics (TXG) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next 10x Genomics dividend payment date?
10x Genomics (TXG) stock does not pay dividends to its shareholders.
What is the beta indicator for 10x Genomics?
10x Genomics (TXG) has a beta rating of 2.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.